Jodie Morrison is recorded as CEO at Q32 Bio Inc. (QTTB) since March 25, 2024 and Board Member at Q32 Bio Inc. (QTTB) since January 1, 2024. The newest filing on record that lists Jodie Morrison as CEO and Board Member at Q32 Bio Inc. (QTTB) is dated April 30, 2026. Q32 Bio Inc. reported in an 8-K filed March 27, 2024 that Jodie Morrison was appointed Chief Executive Officer, effective March 25, 2024. Q32 Bio Inc. reported in an 8-K filed March 27, 2024 that Jodie Morrison was appointed member of the Board, effective March 25, 2024. The proxy statement of Q32 Bio Inc. reports total compensation of $1,558,870 for Jodie Morrison in fiscal 2025, including a base salary of $645,600. Disclosed compensation is on record for 3 fiscal years. Jodie Morrison has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Q32 Bio Inc. on September 8, 2026. Q32 Bio Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Q32 Bio Inc. includes Albert Seymour, Ph.D. (CEO and Board Member), Paul G. Alloway, Ph.D. (CEO and COO), Tim Kelly (CEO and COO) and 7 others.
“On March 25, 2024, the Board appointed Jodie Morrison as our Chief Executive Officer and principal executive officer, Lee Kalowski as our Chief Financial Officer and President and principal financial officer and principal accounting officer, Jason Campagna as our Chief Medical Officer, and Shelia Violette as our Chief Scientific Officer and President of Research.”
Q32 Bio Inc. Form 8-K, filed March 27, 2024
· Read the filing
“Ms. Morrison, age 48, has served as our Chief Executive Officer and a member of the Board since completion of the Merger.”
Q32 Bio Inc. Form 8-K, filed March 27, 2024
· Read the filing
Jodie Morrison on recent calls
“Maybe I'll kick this to Sheila to talk about some of the preclinical models that actually support seeing this and and the why of that yeah so you know there's been a number of studies that have shown these long-term durable responses that you dose in preclinical studies for a period of time stop dosing and then follow…”
“Our Signal AA clinical program has been thoughtfully designed to support a registration-directed program as a next step. The program comprises two parts. On the left, the previously completed Part A trial, and on the right, the ongoing Part B trial.”
